Bajaj Healthcare Limited — Updates, 11-02-2025: Press Release

Bajaj Healthcare has reported strong financial performance for the quarter ending December 2024, showcasing a 171% year-on-year growth in profit after tax from continuing operations. Revenue from operations reached ₹1,227.9 million, reflecting a 13.1% increase from the previous year. Notably, the formulations segment saw impressive growth, with revenues climbing by 58.2% year-on-year, driven by expanding manufacturing capabilities and market demand. The company's overall gross profit rose by 8.0% year-on-year, achieving a gross margin of 50.4%.

Strategically, Bajaj Healthcare has received DCGI approval to manufacture Pimavanserin, enhancing its presence in the CNS segment. The company also secured a CDMO contract for 15 new APIs, signaling growth in its global partnerships. With TGA approval for its API site in Gujarat, it can supply directly to Australia and New Zealand, bolstering its international market reach. The outlook remains positive as Bajaj Healthcare focuses on operational excellence and strategic partnerships, positioning itself as a reliable global pharmaceutical player.